Development and Optimization of Olaparib-Encapsulated Silica Nanocarriers for Enhanced Therapeutic Efficacy in Ovarian Cancer: Cytotoxicity Profiling in HaCaT and SK-OV-3 Cell Models
- 6 January 2026
- journal article
- research article
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (1) , 98
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- pH-responsive silica nanocarriers of olaparib for augmenting anticancer activity: development, characterization, and in vitro cytotoxicity study against MCF-7 breast cancer cells3 Biotech, 2025
- Codelivery of adavosertib and olaparib by tumor-targeting nanoparticles for augmented efficacy and reduced toxicityActa Biomaterialia, 2022
- Editorial: Advanced Liposome ResearchAdvanced Drug Delivery Reviews, 2020
- Mesoporous silica nanoparticles for drug and gene deliveryActa Pharmaceutica Sinica B, 2018
- Targeted delivery of mesoporous silica nanoparticles loaded monastrol into cancer cells: an in vitro studyApplied Nanoscience, 2017
- Chitosan‐Capped Mesoporous Silica Nanoparticles as pH‐Responsive Nanocarriers for Controlled Drug ReleaseChemistry – An Asian Journal, 2013
- Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug DeliveryAdvanced Materials, 2012
- Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers☆Advanced Drug Delivery Reviews, 2008
- Mesoporous Silica Nanoparticles as a Delivery System for Hydrophobic Anticancer DrugsSmall, 2007
- Controlled growth of monodisperse silica spheres in the micron size rangeJournal of Colloid and Interface Science, 1968